Pitt
UPMC
UPCI
CMU
Pawel Kalinski, M.D./Ph.D.
Professor
Department of Surgery
Univeristy of Pittsburgh
HCC Suite 1.46
5117 Centre Avenue
Pittsburgh, PA 15213
office: 412-623-7712
fax: 412-623-7709
email: kalinskip@upmc.edu
The focus of research conducted in Dr. Kalinski’s laboratory is the development of cancer treatments that simultaneously target the induction and effector phase of tumor-specific immune responses and use the paradigms of effective anti-viral immunity. Exposing maturing dendritic cells (DCs) simultaneously to cancer antigens and mediators of anti-viral responses, Dr. Kalinski’s group developed type-1-polarized DC1s with selectively enhanced Th1-, CTL- and NK cell-activating properties and tumor-selective modulation of chemokine production. Combined application of DC1s with interferons, Toll-like receptor ligands and prostaglandin inhibitors, aims to recreate the conditions of viral infection within tumor tissues to enhance the homing of vaccination-induced T cells into tumors and their local anti-tumor functions.
Publications:
Kalinski P. (2012). Regulation of immune responses by prostaglandin E2. J Immunol. 188: 21-28.
Kalinski P, Edington H, Zeh HJ, Okada H, Butterfield LH, Kirkwood JM, Bartlett DL. 92011). Dendritic cells in cancer immunotherapy: vaccines or autologous transplants? Immunol Res. 50: 235-247.
Wong JL, Mailliard RB, Moschos SJ, Edington H, Lotze MT, Kirkwood JM, Kalinski P. (2011). Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells. J Immunother. 34: 270-278.
Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, Kirkwood JM, Storkus WJ, Kalinski P. (2004). alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 64: 5934-5937.